Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis

Prostate

Volumn 71, Issue 2, 2011, Pages 111-124

  Cuffe, Sandra ^a   Dowling, Catherine M ^a   Claffey, James ^a   Pampillõn, Clara ^a   Hogan, Megan ^a   Fitzpatrick, John M ^a   Carty, Michael P ^b   Tacke, Matthias ^a   Watson, R William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

apoptosis; DNA damage; prostate cancer; titanocene dichloride derivatives

Indexed keywords

BIS(BIS 2(N METHYLINDOLYL)METHYLCYCLOPENTADIENY 1)TITANIUM DICHLORIDE; BIS(N,N DIMETHYLAMINO 2(N METHYLPYRROLYL) METHYLCYCLOPENTADIENYL)TITANIUM DICHLORIDE; BIS[(P METHOXYBENZYL)CYCLOPENTADIENYL]TITANIUM DICHLORIDE; BIS[DI(2 N METHYLPYRROLYL)METHYLCYCLOPENTADIENYL]TITANIUM DICHLORIDE; CRYSTAL VIOLET; DNA; PROPIDIUM IODIDE; TITANOCENE DICHLORIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASTRATION; CELL COUNT; CELL CYCLE; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; GENTIAN VIOLET; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORGANOMETALLIC COMPOUNDS; PROSTATIC NEOPLASMS; TITANIUM;

EID: 78650993971     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21227     Document Type: Article

References (36)

1. Donnelly DW, Gavin ATHC,. Cancer in Ireland 1994-2004: A comprehensive report. Northern Ireland Cancer Registry/National Cancer Registry, Ireland; 2009.
2. Small EJ, Reese DM, Vogelzang NJ,. Hormone-refractory prostate cancer: An evolving standard of care. Semin Oncol 1999; 26 (5 Suppl 17): 61-67.
3. Raghavan D, Koczwara B, Javle M,. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997; 33 (4): 566-574.
4. van Brussel JP, Mickisch GH,. Multidrug resistance in prostate cancer. Onkologie 2003; 26 (2): 175-181.
5. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM,. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002; 51 (2): 133-140.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512.
7. Loening SA, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy GP,. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983; 129 (5): 1001-1006.
8. Kopf-Maier P,. Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol 1994; 47 (1): 1-16.
9. Lummen G, Sperling H, Luboldt H, Otto T, Rubben H,. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 1998; 42 (5): 415-417.
10. Kröger N, Kleeberg UR, Mross K, Edler L, Hossfeld DK,. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 2000; 23 (1): 60.
11. Kelter G, Sweeney NJ, Strohfeldt K, Fiebig HH, Tacke M,. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anticancer Drugs 2005; 16 (10): 1091-1098.
12. O'Connor K, Gill C, Tacke M, Rehmann FJ, Strohfeldt K, Sweeney N, Fitzpatrick JM, Watson RW,. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. Apoptosis 2006; 11 (7): 1205-1214.
13. Dowling CM, Claffey J, Cuffe S, Fichtner I, Pampillõn C, Sweeney NJ, Strohfeldt K, Watson RWG, Tacke M,. Antitumor activity of titanocene Y in xenografted PC3 tumors in mice. Lett Drug Des Discov 2008; 5 (2): 141.
14. McEleny K, Coffey R, Morrissey C, Williamson K, Zangemeister-Wittke U, Fitzpatrick JM, Watson RW,. An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate 2004; 59 (4): 419-425.
15. Pampillõn C, Sweeney NJ, Strohfeldt K, Tacke M,. Diheteroarylmethyl substituted titanocenes: A novel class of possible anti-cancer drugs. Inorganica Chimica Acta 2006; 359 (12): 3969.
16. Pampillõn C, Sweeney NJ, Strohfeldt K, Tacke M,. Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs. J Organomet Chem 2007; 692 (11): 2153.
17. Sweeney NJ, Mendoza O, Müller-Bunz H, Pampillõn C, Rehmann F-JK, Strohfeldt K, Tacke M,. Novel benzyl substituted titanocene anti-cancer drugs. J Organomet Chem 2005; 690 (21-22): 4537.
18. Fichtner I, Pampillon C, Sweeney NJ, Strohfeldt K, Tacke M,. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anticancer Drugs 2006; 17 (3): 333-336.
19. Beckhove P, Oberschmidt O, Hanauske AR, Pampillon C, Schirrmacher V, Sweeney NJ, Strohfeldt K, Tacke M,. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anticancer Drugs 2007; 18 (3): 311-315.
20. Catz SD, Johnson JL,. BCL-2 in prostate cancer: A minireview. Apoptosis 2003; 8 (1): 29-37.
21. Altomare DA, Testa JR,. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24 (50): 7455-7464.
22. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275 (5308): 1943-1947.
23. Carroll AG, Voeller HJ, Sugars L, Gelmann EP,. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23 (2): 123-134.
24. Kopf-Maier P, Krahl D,. Tumor inhibition by metallocenes: Ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem Biol Interact 1983; 44 (3): 317-328.
25. Guo M, Guo Z, Sadler PJ,. Titanium(IV) targets phosphoesters on nucleotides: Implications for the mechanism of action of the anticancer drug titanocene dichloride. J Biol Inorg Chem 2001; 6 (7): 698-707.
26. Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR, Kerr DJ,. Anti-proliferative activity and mechanism of action of titanocene dichloride. Br J Cancer 1998; 77 (12): 2088-2097.
27. Tacke M,. The interaction of titanocene Y with double-stranded DNA: A computational study. Lett Drug Des Discov 2008; 5 (5): 332.
28. Durocher D, Jackson SP,. DNA-PK, ATM, and ATR as sensors of DNA damage: Variations on a theme? Curr Opin Cell Biol 2001; 13 (2): 225-231.
29. Abraham RT,. PI 3-kinase related kinases: 'Big' players in stress-induced signaling pathways. DNA Repair (Amst) 2004; 3 (8-9): 883-887.
30. Binz SK, Sheehan AM, Wold MS,. Replication protein A phosphorylation and the cellular response to DNA damage. DNA Repair (Amst) 2004; 3 (8-9): 1015-1024.
31. Lavin MF,. The Mre11 complex and ATM: A two-way functional interaction in recognising and signaling DNA double strand breaks. DNA Repair (Amst) 2004; 3 (11): 1515-1520.
32. Petrini JH,. The mammalian Mre11-Rad50-nbs1 protein complex: Integration of functions in the cellular DNA-damage response. Am J Hum Genet 1999; 64 (5): 1264-1269.
33. Su TT,. Cellular responses to DNA damage: One signal, multiple choices. Annu Rev Genet 2006; 40: 187-208.
34. Lee JH, Paull TT,. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005; 308 (5721): 551-554.
35. Niu H, Erdjument-Bromage H, Pan ZQ, Lee SH, Tempst P, Hurwitz J,. Mapping of amino acid residues in the p34 subunit of human single-stranded DNA-binding protein phosphorylated by DNA-dependent protein kinase and Cdc2 kinase in vitro. J Biol Chem 1997; 272 (19): 12634-12641.
36. Bakkenist CJ, Kastan MB,. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421 (6922): 499-506.